Thus, most studies are based on in vitro expansion protocols with cytokines such as IL-2 or IL-12 [16] prior to ELISPOT assays, limiting the analysis of the ex vivo molecular properties of TAA-specific CD8+ T cells in HCC. This evidence concerns the gene CD8A and hepatocellular carcinoma.